38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality

BACKGROUND: Remdesivir (RDV) reduced time to recovery and mortality in some subgroups of hospitalized patients in the NIAID ACTT-1 RCT compared to placebo. Comparative effectiveness data in clinical practice are limited. METHODS: Using the Premier Healthcare Database, we compared survival for adult...

Descripción completa

Detalles Bibliográficos
Autores principales: Mozaffari, Essy, Chandak, Aastha, Zhang, Zhiji, Liang, Shuting, Thrun, Mark, Gottlieb, Robert L, Kuritzkes, Daniel R, Sax, Paul, Wohl, David, Casciano, Roman, Hodgkins, Paul, Haubrich, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644802/
http://dx.doi.org/10.1093/ofid/ofab466.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644802/
http://dx.doi.org/10.1093/ofid/ofab466.038

Ejemplares similares